TSC2 and kidney neoplasm: We have previously used Tsc2+/- mice in a C57BL/6 mixed strain to show that mTOR inhibitor treatment reduces kidney tumor severity, to investigate the timing of mTOR inhibitor treatment, and to show that addition of prolonged weekly maintenance rapamycin treatment was extremely effective [20,21,61].